Trials / Completed
CompletedNCT00754650
A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia
ML21206 - Bevacizumab in Chronic Lymphocytic Leukemia: A Proof of Concept Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This single arm study evaluated the bone marrow response, safety, and tolerability of 6 months treatment with Avastin (bevacizumab) monotherapy in patients with chronic lymphocytic leukemia. Patients received 8 cycles (21 days duration) of Avastin monotherapy (15mg/kg) with 6 months of follow-up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevacizumab | Bevacizumab was supplied as a sterile liquid in single-use vials. |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2009-03-01
- Completion
- 2009-03-01
- First posted
- 2008-09-18
- Last updated
- 2014-06-26
- Results posted
- 2014-06-26
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT00754650. Inclusion in this directory is not an endorsement.